Business Context and Reporting Period
This Form 8-K Current Report was filed by Reneo Pharmaceuticals, Inc. (trading symbol: RPHM) on May 5, 2023. The filing discloses the entry into material definitive agreements regarding a public offering of common stock and a concurrent private placement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
The filing details two primary capital-raising transactions scheduled to close in early May 2023:
- Public Offering: Sale of 6,875,000 shares of common stock at an offering price of $8.00 per share. Underwriters exercised their option to purchase an additional 1,031,250 shares.
- Net Proceeds (Public Offering): Approximately $58.2 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Private Placement: Sale of 625,000 shares to Abingworth Bioventures 8 LP at the public offering price of $8.00 per share.
- Private Placement Proceeds: Approximately $5.0 million.
- Total Capital Raised: Approximately $63.2 million (combined public and private).
Note: This filing does not provide historical revenue, profit, cash flow, margin, or debt metrics. It focuses exclusively on the terms of the equity offering.
Material Changes and Agreements
The primary material change is the execution of the following agreements:
- Underwriting Agreement: Entered on May 3, 2023, with Jefferies LLC, BofA Securities, Inc., and Piper Sandler & Co. as representatives. The agreement includes a 90-day lock-up period restricting the company from offering or selling additional common stock without underwriter consent.
- Securities Purchase Agreement: Entered on May 2, 2023, with Abingworth Bioventures 8 LP. The company agreed to file a registration statement for the resale of these shares by June 7, 2023.
- Penalty Provision: If the resale registration statement is not filed or declared effective by the agreed dates, the company must pay Abingworth 1.0% of the purchase amount for each 20-day period of delay, increasing by 1.0% for each subsequent 20-day period.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The filing indicates the company intends to use the proceeds to fund its clinical development programs and general corporate purposes, though specific allocation details are not provided in this text. The transactions are subject to customary closing conditions.
Risks and Contingencies:
- Closing Conditions: Both the Public Offering and Private Placement are scheduled to close on or about May 8, 2023, and May 9, 2023, respectively, subject to customary conditions.
- Registration Default Risk: The company faces financial penalties if it fails to timely file or have declared effective the registration statement for the private placement shares.
- Lock-up Restrictions: The company is restricted from issuing new equity for 90 days post-offering without underwriter consent.
Key Facts for Investor Verification
- Verify the final closing date of the Public Offering and Private Placement (expected May 8-9, 2023).
- Confirm the exact net proceeds received after final deduction of all offering expenses.
- Monitor the filing status of the resale registration statement for Abingworth's shares by the June 7, 2023 deadline to avoid penalty payments.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific representations, warranties, and termination provisions.
- Check subsequent filings for the specific allocation of the approximately $63.2 million in raised capital.